Is Sysmex in financial trouble?

Sysmex is not in financial trouble but its FY2026 (ended March 2026) results show real strain: net sales fell 1.7% to ¥500,006 million and operating profit dropped 40.8% to ¥51.8 billion. This decline is tied to China's policy-driven drop in test volumes and distributor destocking rather than to competitors winning customers, and FY2025 results the year before were still growing at double digits.

What is the biggest risk to Sysmex?

The biggest risk is China, where sales fell 18-20% year over year in FY2026 under a new government 'minimal necessity' testing-volume policy, and where low-cost rival Mindray could gain ground. As of the July 2026 assessment, this has not been confirmed as a share loss to competitors, but it is the main open question for the company.

Is Sysmex at risk from AI?

Sysmex faces limited AI risk right now. Danaher's Beckman Coulter shipped an AI-enabled DxH 900 analyzer in December 2023 that competes on smear morphology reading, but Sysmex already covers that task with its own DI-60/CellaVision layer, and there is no evidence yet of Beckman gaining ground.

Who are Sysmex's biggest competitors?

The named competitors to watch are Mindray Medical, a low-cost China rival, and Danaher's Beckman Coulter, which shipped a new AI-enabled analyzer in December 2023. Roche Diagnostics is unusual in being both a 25-year distribution partner (renewed August 2023) and an adjacent competitor, while Siemens Healthineers remains a broader industry peer with no confirmed share shift.

Could a low-cost rival replace Sysmex?

This looks unlikely for now. Despite China's testing slowdown driving an 18-20% year-over-year sales drop there in FY2026, there is no confirmed evidence that Mindray or other rivals are taking meaningful share from Sysmex; the profit decline traces to a government policy shift and distributor destocking rather than customers switching suppliers.

What should I watch to see if Sysmex's China problem is easing?

Management has guided that China sales should stop declining year over year by the second half of FY2027, covering October 2026 through March 2027. A second checkpoint comes by May 2027, when full-year results will show whether FY2027 net sales reach the ¥535 billion guidance issued in May 2026.

Medical technology and health companies · Japan

Sysmex Corporation

sysmex.co.jp ↗

Sysmex makes the blood-testing machines and reagents hospital labs run daily counts on.

Defensible for now

Assessed 31 July 2026 · Evidence as of 31 July 2026

Real protection, with named pressure against it.

On the recordSince 31 July 2026 · Checkable from August 5, 2026 · Every call on the record Checkpoint: Q1 FY2027 earnings, first test of guided recovery from China pricing hit and Japan weakness

The call

Sysmex still leads hematology instruments worldwide, but China's price crackdown and a goodwill writedown just delivered its worst profit drop in years.

Sysmex sells machines and chemicals that hospitals and clinics use to analyze blood samples. The company is difficult to unseat because hospitals get locked into its equipment through regulatory approvals and years of service relationships, and they buy replacement chemicals from Sysmex like razors buy blades. However, profits dropped 41% in the last year because China cut medical-device prices sharply and Japan weakened, hitting a company that built its strength on stable, recurring revenue. The real question is whether China's price pressure spreads to richer markets where Sysmex's competitors like Mindray gain traction, or whether the company can prove its profits bounce back in the next few quarters as it claims.

Why

AI pressure: Sight Diagnostics-class point-of-care AI hematology devices. AI-driven point-of-care blood counters could pull volume from central labs over time, but adoption hasn't dented Sysmex's installed base yet. Could AI do the core job? Unlikely.

Bigger players: Mindray Medical. Mindray sells competing hematology instruments and is pressing hard in China, where new pricing rules already cut into Sysmex's margins. Could a giant copy it? No, they are blocked.

What protects it. Instrument-reagent regulatory clearances and a 190+ country direct sales and service network keep hospitals locked into Sysmex's consumables.

What would change this call

Sysmex Q1/Q2 FY2027 earnings (from Aug 5, 2026) show sales/profit recovery. Would confirm the profit slump was cyclical, not competitive share loss.
Mindray reports hematology revenue growth in US/Europe hospital accounts. Would show China rival converting pricing pressure into developed-market share gains.
Sysmex US hospital hematology share estimate drops materially below ~80%. Would confirm real customer loss in its core stronghold market.

Key numbers

FY2026 operating profit fell 40.8% to Y51.8 billion (2026-03-31)
Goodwill impairment of Y11.2 to 11.6 billion taken (2026-04-28)
Global hematology instrument share about 37.5% (2025-03-31)

Named risks

China national medical device price crackdown continues cutting core hematology revenue. Severity: high
Recurring goodwill impairment risk from subsidiaries like Sysmex Partec and Oxford Gene Technology. Severity: medium
JEOL BioMajesty integration outcome for FY2027 still under review, unproven accretion. Severity: medium
Removal from S&P International 700 and S&P TOPIX indices could reduce passive fund ownership. Severity: low
Successive analyst downgrades (Citigroup, Zacks) signal weakening investor sentiment. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Mindray Medical	gaining on	China's national device price crackdown, reported July 2026, favors Mindray's regional pricing
Beckman Coulter (Danaher)	contesting	Holds ~17% of US hospital hematology share vs Sysmex's ~80% estimate, June 18 2026
Roche Diagnostics	contesting	Roche APAC diagnostics sales down 5% constant FX in H1 2026, similar China headwinds
Siemens Healthineers	contesting	Broad IVD and hematology competitor, no reported share shift as of mid-2026

Questions people ask

Is Sysmex in financial trouble?: Sysmex is not in financial trouble but its FY2026 (ended March 2026) results show real strain: net sales fell 1.7% to ¥500,006 million and operating profit dropped 40.8% to ¥51.8 billion. This decline is tied to China's policy-driven drop in test volumes and distributor destocking rather than to competitors winning customers, and FY2025 results the year before were still growing at double digits.
What is the biggest risk to Sysmex?: The biggest risk is China, where sales fell 18-20% year over year in FY2026 under a new government 'minimal necessity' testing-volume policy, and where low-cost rival Mindray could gain ground. As of the July 2026 assessment, this has not been confirmed as a share loss to competitors, but it is the main open question for the company.
Is Sysmex at risk from AI?: Sysmex faces limited AI risk right now. Danaher's Beckman Coulter shipped an AI-enabled DxH 900 analyzer in December 2023 that competes on smear morphology reading, but Sysmex already covers that task with its own DI-60/CellaVision layer, and there is no evidence yet of Beckman gaining ground.
Who are Sysmex's biggest competitors?: The named competitors to watch are Mindray Medical, a low-cost China rival, and Danaher's Beckman Coulter, which shipped a new AI-enabled analyzer in December 2023. Roche Diagnostics is unusual in being both a 25-year distribution partner (renewed August 2023) and an adjacent competitor, while Siemens Healthineers remains a broader industry peer with no confirmed share shift.
Could a low-cost rival replace Sysmex?: This looks unlikely for now. Despite China's testing slowdown driving an 18-20% year-over-year sales drop there in FY2026, there is no confirmed evidence that Mindray or other rivals are taking meaningful share from Sysmex; the profit decline traces to a government policy shift and distributor destocking rather than customers switching suppliers.
What should I watch to see if Sysmex's China problem is easing?: Management has guided that China sales should stop declining year over year by the second half of FY2027, covering October 2026 through March 2027. A second checkpoint comes by May 2027, when full-year results will show whether FY2027 net sales reach the ¥535 billion guidance issued in May 2026.

Timeline

2026-07-27Sysmex America showcases XR-Series and new CN-9000 hemostasis analyzer at ADLM 2026
2026-07-14Zacks cuts Sysmex rating to strong sell from hold
2026-06-01Sysmex dropped from S&P International 700 and S&P TOPIX indices
2026-05-28Next generation XR-Series hematology platform launched
2026-05-13FY2026 results: net sales Yen500.0B (-1.7%), operating profit Yen51.8B (-40.8%)
2026-04-28Sysmex announces Yen11.2 to 11.6 billion goodwill impairment charge
2026-04-01JEOL clinical chemistry acquisition completes, forms Sysmex BioMajesty Corporation
2026-03-19Citigroup downgrades Sysmex ADR to Hold from strong buy
2026-02-12Sysmex cuts FY2026 guidance citing weak China demand and FX
2025-09-02Sysmex announces acquisition of JEOL's clinical chemistry business

Head to head

Siemens Healthineers vs Sysmex Corporation

Revision history

31 July 2026

First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.

In the same band

Abridge Seegene Olympus Corporation

More in Medical technology and health companies →

Sources

251106_transcript_e
CellaVision: Hematology Instruments Market (2026-06-18)
Sysmex (6869) Q4 2026 Summary (2026-05-13)
Announcement Regarding Impairment Losses
gurufocus.com (2026-07-30)
wikipedia.org (2026-07-30)
Sysmex Expands Portfolio (2025-09-01)
Completion of the Acquisition (2026-03-31)
Recovery underway despite downward forecast revision (2025-11-20)
251105_pr_e
SSMXY Downgraded to Hold Rating by Citigroup (2026-03-19)
Sysmex (SSMXY) to Release Earnings on Wednesday (2026-07-29)